Chimerix, Inc.

NasdaqGM:CMRX Rapport sur les actions

Capitalisation boursière : US$801.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Chimerix Résultats passés

Passé contrôle des critères 0/6

Chimerix a connu une croissance annuelle moyenne de ses bénéfices de 15.5%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 33.8% par an. Les revenus ont augmenté de en baisse à un taux moyen de 7.4% par an.

Informations clés

15.54%

Taux de croissance des bénéfices

22.62%

Taux de croissance du BPA

Biotechs Croissance de l'industrie17.04%
Taux de croissance des recettes-7.36%
Rendement des fonds propres-72.64%
Marge nette-41,691.98%
Dernière mise à jour des bénéfices31 Dec 2024

Mises à jour récentes des performances passées

Recent updates

Seeking Alpha • Feb 20

Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Summary The company holds the potential to have the first approval of dordaviprone for the treatment of recurrent H3 K27M mutant high-grade glioma patients; PDUFA with a Priority Review date of August 18th, 2025. The global brain tumor therapeutics market is expected to grow to $5.28 billion by 2030; the Company notes that it could obtain >$1 billion in revenues in the United States alone. Phase 3 ACTION study using dordaviprone for the treatment of front-line H3 K27M mutant high-grade glioma patients to have OS interim data readout in Q3 of 2025. FDA approval of dordaviprone for the treatment of patients with recurrent H3 K27M mutant high-grade glioma could allow the company to receive a Priority Review Voucher, which it could keep or sell. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Summary Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in diffuse midline glioma bolster confidence in FDA approval, despite potential timeline uncertainties. Financially, CMRX has a cash runway of 6–7 quarters, sufficient to reach an FDA decision, but risks of dilution remain. Given the recent market surge and promising outlook, I maintain a favorable rating on CMRX stock, anticipating significant market capitalization growth. Read the full article on Seeking Alpha
Article d’analyse • Jul 16

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Aug 23

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Initiation of phase 3 ACTION study using ONC201 for treatment of glioma patients who harbor the H3 K27M mutation is expected in the 2nd half of 2022. Interim results from the ACTION study are expected in early 2025, with final results expected in 2026. Proof of concept data using ONC201 has already been established in two phase 2 studies; in patients with H3 K27M mutation gliomas and neuroendocrine tumors. Additional imipridones being developed in the pipeline are ONC206 and ONC212 for oncology indications; CMX521 being advanced as prophylactic and treatment for Covid-19. Chimerix, Inc. (CMRX) is a great speculative biotech that should be on your radar. While it is still a risky longer-term play, I believe it could have value based on established proof of concept using ONC201 for the treatment of patients with H3 K27M-mutant glioma. In a phase 2 study, it showed to improve overall survival rates in this specific population, which I will show below. The only downside is that the first interim analysis is not expected until early 2025 with final data not coming out until 2026. However, ONC201 is also being explored in a phase 2 study in neuroendocrine tumors. Such neuroendocrine tumors being explored are Pheochromocytoma/paraganglioma. Initial data was revealed which established some proof of concept of the mechanism of action. Even then, it is working on a second generation imipridone known as ONC206 which is much improved compared to 1st generation ONC201. It is believed that ONC206 provides greater anti-tumor activity compared to ONC201 and thus it is also being advanced in the pipeline. The biotech also entered into an agreement with Emergent BioSolutions ((EBS)) for the sale of worldwide rights to TEMBEXA for a $225 million upfront payment, potential milestone payments and double-digit royalties on net sales as well. It is important to note that this agreement is still in the process of being completed. This agreement relies on additional items being executed. If the agreement goes through with EBS, then the biotech will have enough cash into 2027. Lastly, it is in the process of developing an improved oral formulation of CMX521 as a prophylactic and treatment of SARS-CoV-2 (Covid-19) in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative ((READDI)). While early in the process and already many approved treatments in this space, I believe it could still act as a catalyst if it is successfully advanced. It is believed that animal data will be released in the 2nd half of 2022 on such an improved oral formulation for CMX521 for Covid-19. With a growing pipeline, plus some established proof of concept of ONC201 in a rare brain glioma and neuroendocrine tumors, I believe it is a great speculative biotech play to look into. Imipridone ONC201 Could Possibly Greatly Improve Overall Survival Rates For Rare Gliomas The main drug in Chimerix's pipeline would be ONC201, which is being developed for the treatment of patients with gliomas who harbor the H3 K27M mutation. What occurs with respect to this specific type of glioma? What occurs is the H3K27M mutation itself puts in a new amino acid known as H3, which promotes a gene expression that enable tumor growth to occur. Patients with this type of glioma have poor prognosis and definitely need new types of treatments to be approved. Before diving into ONC201 clinical results, it's important to understand what the drug actually is. Again, it is an imipridone which targets G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease p (ClpP), resulting in cancer death. Cell death happens with the induction of the integrated stress response and upregulation pathway of apoptotic (cell death) factors, such as tumor necrosis factor ((TNF)) related apoptosis-inducing ligand ((TRAIL)). More specifically, it selectively induces cell death by binding and altering activity of DRD2 (Selectively coupled G-protein receptor) and ClpP. This is further established with the following action: DRD2 antagonism is responsible for inhibiting Ras signaling pathway that cancer has ClpP degrades excess amount of mitochondrial proteins which are important for the cancer cell to be viable Remember above when I stated that H3 K27M mutation uses amino acid H3 to promote gene expression for the cancer? Well, ONC201 was established to alter this gene expression making it sensitive to the drug itself. All these actions are what are put in place to specifically treat glioma patients who harbor the H3 K27M mutation. Moving onto the program advancement at hand, the company intends to initiate a phase 3 study in the 2nd half of 2022 known as ACTION. This is going to be a randomized late-stage study using ONC201 for the treatment of newly diagnosed diffuse glioma patients whose tumors harbor the H3 K27M mutation. It is expected that about 450 patients will be randomized 1:1:1 to receive doses as followed: 625 mg ONC201 once per week 625 mg ONC201 twice per week Placebo The primary endpoint of this study is overall survival ((OS)). Patients will first be treated with radiation and then be randomized to one of the dosing groups noted directly above. As far as catalysts go for this study, it could be quite some time to see data. It is said that the first interim analysis for results is not expected until 2025. From there, final data from this ACTION study is not expected until 2026. The thing is that it may be a good market to tap into despite the fact how rare the H3 K27M mutation glioma is. Chimerix believes it can earn above $500 million in sales annually should it ultimately get ONC201 to market for this specific population. Despite results taking time to come out, it's important to note that there is a great shot at clinical success. That's because ONC201 monotherapy was able to achieve an overall response rate ((ORR)) of 30% by RANO HGG and/or LGG by dual reader BICR. Even better, is what those treated with this drug obtained in terms of overall survival rates. For the H3 K27M recurrent glioma patients given ONC201, overall survival at 12 months and 24 months was 57% and 35%, respectively, whereas historical control at 12 months and 24 months was 27.5% and 6.4%, respectively. What does this show? This shows that with the biotech specifically targeting patients with this H3 K27M mutation by using ONC201, it can improve overall survival for them. Proof Of Concept For ONC201 In Treatment Of Patients With Neuroendocrine Tumors In addition to some proof of concept being established in a phase 2 study with ONC201 in patients with H3 K27M mutated gliomas, the drug had also seen some mechanism of action in patients with neuroendocrine tumors. One neuroendocrine tumor being explored is paraganglioma. A paraganglioma is a type of neuroendocrine tumor that forms near certain blood vessels and nerves outside of the adrenal glands. The adrenal glands being affects is not a very good thing, considering they are responsible for making hormones which control many functions in the body. In an open-label phase 2 investigator-initiated study with 30 patients, treatment with ONC201 performed pretty well. The cohort of paraganglioma patients who were dosed with ONC201 once a week performed better than the other cohort of patients dosed twice a week with ONC201. For these patients who were dosed once weekly with ONC201, the outcome was as follows: 5 out of 10 patients (50%) achieved a partial response ((PR)) 2 out of 10 patients achieved stable disease ((SD)) The other neuroendocrine tumor also being evaluated with the use of this drug is Pheochromocytoma, which is a hormone secreting tumor that can occur in the adrenal glands. Additional Shots On Goal With Imipridones ONC206 And ONC212
Article d’analyse • Jul 20

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 06

Chimerix: Down But Not Out

Today, we revisit an interesting small-cap concern called Chimerix that trades for around two bucks a share, and under cash value. The company recently announced a deal to sell off its one approved drug for over $200 million, which was received negatively by the market. Chimerix will now pivot fully to developing the other parts of its pipeline. We revisit the investment case around Chimerix in the paragraphs below.
Seeking Alpha • Jan 05

Chimerix: Searching For Clarity

Today, we put Chimerix, Inc. in the spotlight for the first time. The company recently received an FDA approval and has several other promising compounds in development. A full investment analysis is provided in the paragraphs below.
Article d’analyse • Dec 24

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Article d’analyse • Sep 16

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse • Jun 08

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse • May 13

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

With the business potentially at an important milestone, we thought we'd take a closer look at Chimerix, Inc.'s...

Ventilation des recettes et des dépenses

Comment Chimerix gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

NasdaqGM:CMRX Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
31 Dec 240-88220
30 Sep 240-8420-1
30 Jun 240-85250
31 Mar 240-83250
31 Dec 230-82250
30 Sep 231-85250
30 Jun 2334180210
31 Mar 2334176230
31 Dec 2234172230
30 Sep 2233154226
30 Jun 221-106220
31 Mar 221-10120-12
31 Dec 212-173190
30 Sep 213-145180
30 Jun 215-138160
31 Mar 216-1311512
31 Dec 205-44140
30 Sep 2011-35130
30 Jun 2011-98130
31 Mar 2011-105150
31 Dec 1913-113190
30 Sep 1911-124210
30 Jun 199-66220
31 Mar 199-67250
31 Dec 187-69240
30 Sep 184-74260
30 Jun 185-75280
31 Mar 184-73270
31 Dec 174-71270
30 Sep 175-67250
30 Jun 174-66240
31 Mar 176-68250
31 Dec 166-76250
30 Sep 167-99290
30 Jun 168-115320
31 Mar 1611-121320
31 Dec 1511-117310
30 Sep 159-100270
30 Jun 158-84250
31 Mar 154-71200
31 Dec 144-59180
30 Sep 144-47140
30 Jun 143-37100

Des revenus de qualité: CMRX n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: CMRX n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: CMRX n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 15.5% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de CMRX au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: CMRX n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 43% ).

Rendement des fonds propres

ROE élevé: CMRX a un retour sur capitaux propres négatif ( -72.64% ), car il n'est actuellement pas rentable.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2025/04/22 22:26
Cours de l'action en fin de journée2025/04/17 00:00
Les revenus2024/12/31
Revenus annuels2024/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Chimerix, Inc. est couverte par 15 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Geoffrey MeachamBarclays
Debjit ChattopadhyayBrean Capital Historical (Janney Montgomery)
Ritu BaralCanaccord Genuity